| Business Summary | | Taro
Pharmaceutical
Industries
Ltd.
commenced
operations
as
a
manufacturer
of
solid
dosage
form
products,
but
an
agreement
with
American
Home
Products
Corporation
in
1954
allowed
the
Company
to
expand
operations
to
include
sterile
products.
The
Company
entered
the
steroid
market
following
an
agreement
with
the
Schering
Corporation
in
1955.
In
1957,
an
agreement
with
Endo
Laboratories
provided
Taro
with
products
such
as
Percodan
and
Coumadin,
which
Taro
continues
to
manufacture
and
sell
in
Israel
today. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | TARO
manufactures,
markets
and
distributes
OTC
and
prescription
pharmaceuticals
primarily
in
the
Unites
States,
Canada
and
Israel,
offering
topical
corticosteroids
and
antifungal
cream
products.
For
the
six
months
ended
6/30/01,
sales
rose
39%
to
$64.7
million.
Net
income
totaled
$8.8
million
up
from
$3.7
million.
Revenues
benefited
from
introduction
of
the
CB
Cream
and
other
new
products.
Earnings
also
benefited
from
increases
in
gross
margins
due
to
introduction
of
CB
Cream. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Barrie Levitt, M.D. | Chairman | A. Levitt | Pres,
Director | Eric Hills | Vice
Chairman | Daniel Moros, M.D. | Vice
Chairman | K. Connelly | Sr.
VP, CFO |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|